BioXcel Therapeutics, Inc.(BTAI)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

BioXcel Therapeutics, Inc. (BTAI) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores BTAI at 6.2/100 on a 32-signal composite quality model, placing it at rank #2,952 of 2,961 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), BioXcel Therapeutics, Inc. reports quarterly revenue of $182.0K, net income of $-14.7M, free cash flow of $-6.1M. Top institutional holders of BTAI by reported 13-F value include MILLENNIUM MANAGEMENT, OAKTREE CAPITAL MANAGEMENT, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. BTAI trades on the Nasdaq exchange and files with the SEC under CIK 1720893. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BTAI daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BioXcel Therapeutics, Inc. directly from SEC EDGAR.